{"product_id":"collegiumpharma-business-model-canvas","title":"Collegium Pharmaceutical Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUnlock a pharma strategic playbook with our Business Model Canvas for investors and founders\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock Collegium Pharmaceutical's strategic playbook with our Business Model Canvas—clarifies value propositions, maps revenue and cost drivers, and exposes partnership leverage. This concise, actionable guide is ideal for investors, consultants, and founders. Purchase the full Canvas to get editable Word \u0026amp; Excel files and immediate, usable insights.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eContract manufacturers (CMOs)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eExternal CMOs provide GMP-compliant production (per FDA 21 CFR Parts 210\/211) for Collegium’s abuse-deterrent and extended-release products, enabling scalable output across capsules and suspensions. Industry estimates put global pharmaceutical contract manufacturing at over $150 billion in 2024, underscoring capacity and cost benefits. Dual-sourcing arrangements reduce supply interruptions and support continuity of care. Rigorous technology transfer and process validation ensure consistent performance at scale.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical and research organizations (CROs\/academia)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCROs and academic centers support Collegium’s preclinical programs, clinical trials and real-world evidence generation in pain and CNS, leveraging a CRO sector that exceeded $60 billion in 2024 to scale operations. These partners accelerate study execution and site activation—industry studies report up to 30% faster start‑ups—and help ensure data integrity. KOL collaborations inform protocol design and interpretation, while access to specialized pain\/CNS models strengthens differentiation claims.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePayers, PBMs, and group purchasing organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMarket-access partners—payers, PBMs, and GPOs—drive formulary positioning, step edits, and utilization management; PBMs manage roughly 80% of US prescription drug claims, shaping access and pricing. Value-based contracts and outcomes data support coverage and reimbursement decisions, while GPOs, which represent purchasing for about 80% of U.S. hospitals, streamline institutional buying and compliance. Ongoing engagement aligns clinical and economic value with policy.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDistributors and specialty pharmacies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eWholesale distributors provide national coverage and inventory management (reaching 90%+ of pharmacies) and manage cold chain where needed; specialty pharmacies deliver prior authorization support, adherence programs, and coordinate REMS for products like Xtampza ER in 2024. Real-time data feeds (EDI, claims) inform demand planning and patient support; contracting optimizes service levels and distribution fees across the network.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCoverage: 90%+ pharmacy reach\u003c\/li\u003e\n\u003cli\u003eServices: PA, adherence, REMS coordination (Xtampza ER, 2024)\u003c\/li\u003e\n\u003cli\u003eData: EDI\/claims for forecasting\u003c\/li\u003e\n\u003cli\u003eContracts: service-level and fee optimization\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulators and safety\/advocacy stakeholders\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRegulatory bodies define labeling, risk mitigation and post‑marketing commitments, with the FDA maintaining REMS for ER\/LA opioids to ensure safe use. Safety organizations and patient advocates shape responsible opioid stewardship and targeted education to lower misuse. PDMPs operate in all 50 states, and transparent engagement with clinicians and communities builds trust.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eREMS: FDA‑mandated for ER\/LA opioids\u003c\/li\u003e\n\u003cli\u003ePDMPs: integration across all 50 states\u003c\/li\u003e\n\u003cli\u003eEducation \u0026amp; advocacy: reduce misuse, build clinician\/community trust\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCMOs\/CROs\/PBMs scale access: manufacturing \u0026gt; \u003cstrong\u003e$150B\u003c\/strong\u003e, trials \u0026gt; \u003cstrong\u003e$60B\u003c\/strong\u003e, PBMs \u003cstrong\u003e80%\u003c\/strong\u003e\n\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCMOs supply GMP production for abuse‑deterrent ER products, supporting scale; contract manufacturing market \u0026gt;$150B in 2024. CROs and academic sites accelerate trials and RWE (CRO market \u0026gt;$60B, faster start‑ups ~30%). Payers\/PBMs\/GPOs and distributors shape access—PBMs manage ~80% of US claims; wholesale reach 90%+ pharmacies.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePartner\u003c\/th\u003e\n\u003cth\u003eRole\u003c\/th\u003e\n\u003cth\u003e2024 Metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCMOs\u003c\/td\u003e\n\u003ctd\u003eManufacturing\u003c\/td\u003e\n\u003ctd\u003e$150B market\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCROs\u003c\/td\u003e\n\u003ctd\u003eTrials\/RWE\u003c\/td\u003e\n\u003ctd\u003e$60B market\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePBMs\/Distributors\u003c\/td\u003e\n\u003ctd\u003eAccess\/Distribution\u003c\/td\u003e\n\u003ctd\u003e80% claims \/ 90%+ pharmacies\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA comprehensive Business Model Canvas tailored to Collegium Pharmaceutical’s strategy, detailing customer segments, channels, value propositions, revenue streams and key activities across the 9 BMC blocks. Ideal for investors and analysts, it links competitive advantages with SWOT insights to support strategic decisions and funding discussions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eHigh-level view of Collegium Pharmaceutical’s business model with editable cells to quickly pinpoint pain-relief product, R\u0026amp;D, regulatory and distribution levers—perfect for boardrooms, team collaboration, or comparing strategic options at a glance.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAbuse-deterrent R\u0026amp;D and formulation engineering\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDesign and optimize tamper-resistant and extended-release technologies for opioids and CNS agents, focusing on matrix and crush-resistant systems to deter misuse. Conduct excipient screening, in vitro manipulation and dissolution studies plus PK\/PD bridging to support bioequivalence and safety. Protect innovations via patents and trade secrets while iterating formulations based on FDA\/regulatory feedback and real-world misuse patterns amid 110,000+ US overdose deaths (CDC provisional 2023).\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical development and evidence generation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRun randomized and real‑world studies in 2024 to demonstrate efficacy, safety, and differentiation versus standard of care, leveraging Xtampza ER’s FDA approval in 2016 as clinical anchor. Generate PROs, health‑economics and RWE to support payers and prescribers. Maintain continuous pharmacovigilance and signal detection programs. Publish and present findings at major conferences to strengthen credibility.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory strategy and compliance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEngage FDA and global agencies on NDAs, sNDAs, labeling updates and REMS (FDA opioid REMS established 2012) to secure approvals and risk mitigation; maintain GMP, GDP and GCP across manufacturing, distribution and trials to meet global regulatory standards. Manage post-marketing commitments and expedited safety reporting (15 calendar days for serious unexpected AEs) and prepare for inspections with proactive CAPAs implementation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCommercialization and market access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eCollegium secures formulary coverage and negotiates contracts while managing rebates and chargebacks, deploying field sales, medical affairs, and payer teams to educate clinicians and payers and execute brand strategy, digital engagement, and KOL programs; teams monitor utilization controls and rapidly address access barriers to preserve prescription flow.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCoverage: \u0026gt;90% US lives (commercial\/Medicare\/Medicaid)\u003c\/li\u003e\n\u003cli\u003eRebates\/chargebacks: contract-driven, impacts net price\u003c\/li\u003e\n\u003cli\u003eField + payer + med affairs: integrated access model\u003c\/li\u003e\n\u003cli\u003eDigital + KOL: drives adoption, reduces prior authorization delays\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupply chain and quality management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eSupply chain and quality management centers on forecasting demand, planning production, and managing inventories across wholesalers and pharmacies while qualifying suppliers, overseeing CMOs, and auditing quality systems for regulated opioids like Xtampza ER.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eserialization \u0026amp; controlled substance handling\u003c\/li\u003e\n\u003cli\u003esupplier qualification \u0026amp; CMO oversight\u003c\/li\u003e\n\u003cli\u003einventory planning \u0026amp; continuity plans to prevent stockouts\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTamper-resistant ER opioids: develop, trial and secure payer access amid 110,000+ US OD deaths\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDesign\/optimize tamper‑resistant extended‑release opioids; iterate via excipient screening, PK\/PD bridging and real‑world misuse data (110,000+ US OD deaths, CDC provisional 2023). Run 2024 RCTs and RWE vs SOC; generate PROs and HEOR for payers. Maintain regulatory engagement (Xtampza ER FDA 2016), REMS compliance, GMP\/GCP, supply continuity and payer\/formulary access (\u0026gt;90% US lives).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS OD deaths\u003c\/td\u003e\n\u003ctd\u003e110,000+ (2023 prov.)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eXtampza ER FDA\u003c\/td\u003e\n\u003ctd\u003e2016\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFormulary coverage\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;90% US lives\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe Collegium Pharmaceutical Business Model Canvas you see here is the actual deliverable, not a mockup. When you purchase, you’ll receive this exact file—complete, editable, and formatted—for immediate download. No surprises: what you preview is what you’ll own.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eesources\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProprietary formulation platforms and IP\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePatents and trade secrets protecting Xtampza ER and related abuse-deterrent, extended-release designs (FDA approval 2016) provide commercial defensibility. Collegium's materials science and process know-how reduces development timelines and supports manufacturing scale-up. Freedom-to-operate enables lifecycle management and incremental filings. The IP portfolio is leveraged for licensing and partnership negotiations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory approvals and labeling\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eApproved in 2016, Xtampza ER’s labeled indications and abuse-deterrent claims provide Collegium with differentiated market access and promotional positioning versus immediate-release opioids.\u003c\/p\u003e\n\u003cp\u003eLongstanding REMS engagement since approval and internal compliance frameworks reduce regulatory and litigation risk by ensuring controlled-distribution and prescriber education.\u003c\/p\u003e\n\u003cp\u003eTargeted supplemental approvals and label updates have been used to broaden indications and lifecycle exclusivity, while established FDA rapport accelerates review of formulation and labeling variations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCommercial and medical teams\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCollegium (NASDAQ: COLL) leverages specialty sales, account management and medical affairs to target prescribers and payers, supported in 2024 by a national commercial field force of about 150 reps. Payer relations and HEOR teams quantify value—Collegium cited real-world and economic models in 2024 to support formulary placement. Field reimbursement and patient services handled thousands of access cases in 2024 to reduce initiation barriers. KOL networks amplified scientific messaging through peer forums and publications during 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing and quality network\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCollegium relies on qualified CMOs, validated processes and a certified QMS to ensure reliable supply of its opioid formulations; analytical methods and rigorous release testing safeguard potency and performance. Redundant manufacturing capacity and dual-sourcing strategies mitigate disruptions, while serialization and controlled-substance tracking meet FDA and DEA regulatory requirements.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\u003c\/ul\u003e\n\u003cli\u003eQualified CMOs and QMS\u003c\/li\u003e\n\u003cli\u003eValidated analytics \u0026amp; release testing\u003c\/li\u003e\n\u003cli\u003eRedundant capacity\/dual sourcing\u003c\/li\u003e\n\u003cli\u003eSerialization and controlled-substance controls\u003c\/li\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eData assets and systems\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eClaims, specialty pharmacy, and distributor data feed prescribing, demand shaping and adherence monitoring for Collegium, linking refill patterns to patient support interventions. Safety databases underpin pharmacovigilance and risk management, meeting FDA 15-day expedited reporting for serious adverse events. Digital platforms deliver HCP education and patient support while advanced analytics enable forecasting, segmentation and targeted outreach.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eClaims-data\u003c\/li\u003e\n\u003cli\u003eSpecialty-pharmacy\u003c\/li\u003e\n\u003cli\u003eDistributor-logs\u003c\/li\u003e\n\u003cli\u003ePV-15d\u003c\/li\u003e\n\u003cli\u003eDigital-HCP\u003c\/li\u003e\n\u003cli\u003eAnalytics-forecasting\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAbuse-deterrent ER drug: \u003cstrong\u003e~150\u003c\/strong\u003e reps, \u003cstrong\u003e15\u003c\/strong\u003e-day PV\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePatented abuse-deterrent Xtampza ER (FDA approval 2016) plus materials-science know-how and freedom-to-operate underpin commercial defensibility. Commercial team (~150 reps in 2024) and HEOR\/payer work drove formulary access; patient services handled thousands of access cases in 2024. Qualified CMOs, validated QMS and dual sourcing secure supply; PV systems meet FDA 15-day reporting.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eResource\u003c\/th\u003e\n\u003cth\u003e2024 metric\u003c\/th\u003e\n\u003cth\u003eNote\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCommercial field force\u003c\/td\u003e\n\u003ctd\u003e~150 reps\u003c\/td\u003e\n\u003ctd\u003enational specialty coverage\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatient access\u003c\/td\u003e\n\u003ctd\u003ethousands cases\u003c\/td\u003e\n\u003ctd\u003ereduces initiation barriers\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory\/PV\u003c\/td\u003e\n\u003ctd\u003ePV 15-day\u003c\/td\u003e\n\u003ctd\u003eexpedited SAE reporting\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eV\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ealue Propositions\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEffective pain relief with deterrence features\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMedicines designed to provide sustained analgesia while resisting common tampering methods support safer prescribing without compromising efficacy, aligning with payer and prescriber demand as opioid-related harms remain high (CDC reported 107,622 drug overdose deaths in 2021). By addressing regulatory and societal concerns around misuse, abuse-deterrent formulations can improve formulary positioning and reimbursement prospects. Differentiation can protect market share and justify premium pricing.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRisk mitigation for prescribers and payers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCollegium’s REMS-compliant programs, education, and monitoring tools — maintained as of 2024 — align with FDA’s 2012 ER\/LA opioid REMS framework and lower misuse and diversion risks for products like Xtampza ER (approved 2016). Clear labeling and peer-reviewed evidence facilitate responsible prescribing. Published outcomes and HEOR analyses support payer coverage discussions, while centralized patient-access services reduce administrative burden through streamlined prior authorization and support pathways.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient-centered access and adherence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAs of 2024 Collegium Pharmaceutical (Nasdaq: COLL) supports patients on FDA‑approved Xtampza ER with prior authorization, copay assistance, and education through its patient support services; adherence programs and refill reminders are used to improve persistence. Clear instructions and tamper‑resistant packaging enhance safe use, while multichannel support (phone, digital, pharmacy) boosts satisfaction and outcomes.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReliable, compliant supply\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eReliable, compliant supply minimizes stockouts through robust manufacturing and inventory controls. Controlled substance handling follows DEA scheduling and chain-of-custody protocols. DSCSA serialization and track-and-trace implementation after 2023 milestones add transparency. Consistent quality drives provider confidence.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRobust inventory: fewer stockouts\u003c\/li\u003e\n\u003cli\u003eDEA-compliant handling\u003c\/li\u003e\n\u003cli\u003eDSCSA serialization\/traceability\u003c\/li\u003e\n\u003cli\u003eConsistent quality → provider trust\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEvidence-backed differentiation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eClinical and real-world data support safety and efficacy against persistent opioid-related unmet needs; peer-reviewed publications and KOL endorsements reinforce prescriber confidence. Health economic analyses indicate cost-effectiveness versus non-abuse-deterrent alternatives, and ongoing post‑marketing and pipeline research in 2024 continues to drive lifecycle value.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eEvidence: peer-reviewed publications and real-world studies\u003c\/li\u003e\n\u003cli\u003eTrust: KOL endorsements and clinical uptake\u003c\/li\u003e\n\u003cli\u003eValue: health economic analyses vs alternatives\u003c\/li\u003e\n\u003cli\u003eMomentum: 2024 post‑marketing and pipeline research\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAbuse-deterrent opioids delivering sustained analgesia with REMS compliance and traceable supply\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCollegium offers abuse‑deterrent opioids delivering sustained analgesia while reducing tampering risk, aligning with prescriber, payer, and REMS expectations; REMS compliance maintained in 2024. Xtampza ER (approved 2016) is supported by peer‑reviewed and HEOR evidence and patient‑support services, easing access and adherence. Supply controls and DSCSA traceability reduce stockout and diversion risks.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003eEvidence\u003c\/th\u003e\n\u003cth\u003e2024 status\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSafer analgesia\u003c\/td\u003e\n\u003ctd\u003ePeer‑review, HEOR\u003c\/td\u003e\n\u003ctd\u003eREMS maintained\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAccess\/support\u003c\/td\u003e\n\u003ctd\u003ePatient services\u003c\/td\u003e\n\u003ctd\u003ePrior auth\/copies assisted\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Relationships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical education and support\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMedical affairs delivers scientific exchange, guideline updates, and case support to clinicians, while CME and targeted training emphasize appropriate use and abuse-deterrence to preserve patient safety. Responsive MSLs address complex clinical and formulary questions in real time, supporting product uptake and payer dialogues. Sustained clinician education drives prescribing confidence and loyalty, reinforcing safe prescribing practices.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePayer and PBM account management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDedicated teams manage contracts, rebates and outcomes commitments, coordinating payer and PBM account management to secure access and performance metrics.\u003c\/p\u003e\n\u003cp\u003eRegular quarterly business reviews align utilization controls and value; the top three PBMs managed roughly 80% of US prescription claims in 2024, making these reviews critical.\u003c\/p\u003e\n\u003cp\u003eData sharing and HEOR strengthen formulary and outcomes discussions, and rapid resolution of access issues preserves patient continuity and reduces treatment disruption.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient services and adherence programs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCollegium's hub services streamline benefits verification and prior authorization submissions, achieving rapid clearance times that cut initiation delays and administrative costs; in 2024 the company reported expanded hub capacity supporting thousands of enrollments. Copay assistance and bridge programs lower out-of-pocket burdens and have been shown to reduce treatment discontinuation by around 30%, improving retention. Nurse educators and digital tools provide counseling and adherence reminders to support safe use, while systematic feedback loops from patients and providers drive continuous program refinement and quality metrics tracking.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInstitutional engagement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHospital and IDN liaisons secure pathway inclusion and manage stocking across roughly 6,090 U.S. hospitals and about 1,300 IDNs (AHA\/industry 2023), while GPO contracting streamlines procurement, covering over 80% of hospital purchasing; quality and safety teams jointly develop protocols and in-service training reinforces pharmacy and nursing adoption.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHospitals: 6,090 (AHA 2023)\u003c\/li\u003e\n\u003cli\u003eIDNs: ~1,300\u003c\/li\u003e\n\u003cli\u003eGPO coverage: \u0026gt;80% of hospital purchasing\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePharmacovigilance and quality responsiveness\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCollegium maintains 24\/7 safety reporting and inquiry channels to build trust and meet regulatory expectations; FDA expedited reporting timelines (7-day for death, 15-day for serious\/ unexpected) guide rapid action. The company conducts swift investigations and communicates safety signals to protect patients, handling product quality complaints with transparent documentation. Aggregated safety and quality insights drive ongoing risk mitigation.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e24\/7 reporting\u003c\/li\u003e\n\u003cli\u003eFDA 7\/15-day timelines\u003c\/li\u003e\n\u003cli\u003eTransparent complaint handling\u003c\/li\u003e\n\u003cli\u003eAggregate signal-driven mitigation\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedical affairs + hub\/payer model secures top PBMs access, \u003cstrong\u003e80%\u003c\/strong\u003e reach\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCollegium combines medical affairs, MSLs, hub services and payer teams to drive safe prescribing, rapid access and payer contracting, targeting the top 3 PBMs that handled ~80% of US claims in 2024. Hub and copay programs supported thousands of enrollments in 2024 and cut discontinuation ~30%. 24\/7 safety reporting aligns with FDA 7\/15-day timelines to protect patients.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTop 3 PBMs (2024)\u003c\/td\u003e\n\u003ctd\u003e~80% claims\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospitals (AHA 2023)\u003c\/td\u003e\n\u003ctd\u003e6,090\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIDNs\u003c\/td\u003e\n\u003ctd\u003e~1,300\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGPO coverage\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;80%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDiscontinuation reduction\u003c\/td\u003e\n\u003ctd\u003e~30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ehannels\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eField sales to specialty prescribers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eField sales teams engage directly with pain specialists, anesthesiologists, and select PCPs to drive appropriate initiation of our opioid analgesic portfolio. Messaging emphasizes differentiation, safety features, and appropriate use, supported by samples and tailored educational materials. Sample distribution and in-office training facilitate early adoption, while territory deployment targets clinical demand hubs to maximize prescriber reach.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eWholesale distribution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNational wholesalers AmerisourceBergen, McKesson and Cardinal Health route Collegium products to retail and hospital pharmacies, a channel that accounted for roughly 85% of US pharmaceutical distribution in 2024. Service-level agreements (OTIF and replenishment cadence) ensure timely replenishment and inventory visibility. Contracting governs chargebacks, fees and inventory policies. Real-time EDI\/data feeds support forecast accuracy and reduce stockouts.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialty pharmacy network\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCurated specialty pharmacies manage prior authorization, REMS compliance, and proactive adherence outreach, leveraging enhanced data capture to enable real-time patient support; specialty drugs represented about 54% of US drug spending in 2024. Cold-to-warm transfers reduce prescription abandonment by ensuring live pharmacist engagement, while performance guarantees align incentives between Collegium and dispensing partners to drive adherence and cost-effective outcomes.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInstitutional and GPO channels\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eContracts with hospitals and GPOs secure formulary access and standardized pricing, supporting inpatient and perioperative uptake; pathway inclusion (protocols\/order sets) drives use across settings. In 2024 approximately 6,000 US hospitals inform P\u0026amp;T decisions; 340B and compliance workflows are actively managed while targeted education supports adoption.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eContracts: formulary access, uniform pricing\u003c\/li\u003e\n\u003cli\u003ePathway inclusion: inpatient\/periop uptake\u003c\/li\u003e\n\u003cli\u003e340B\/compliance: managed workflows\u003c\/li\u003e\n\u003cli\u003eEducation: supports P\u0026amp;T and protocol adoption\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital and EMR-enabled engagement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eEMR order sets and eRx prompts streamline prescribing, increasing guideline-concordant orders by ~20–30% per 2024 health IT analyses; HCP portals and webinars provide on-demand CME with 40–60% engagement rates; patient apps and SMS programs improved medication adherence 10–25% in 2024 trials; SEO and content marketing drive ~50% of digital referrals for informed stakeholders in 2024.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eEMR\/eRx: +20–30% guideline concordance\u003c\/li\u003e\n\u003cli\u003eHCP portals\/webinars: 40–60% engagement\u003c\/li\u003e\n\u003cli\u003ePatient apps\/SMS: +10–25% adherence\u003c\/li\u003e\n\u003cli\u003eSEO\/content: ~50% digital referrals (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eChannels: Wholesalers \u003cstrong\u003e~85%\u003c\/strong\u003e, Specialty \u003cstrong\u003e54%\u003c\/strong\u003e, EMR +20–30%\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCollegium leverages field sales, national wholesalers, specialty pharmacies and hospital\/GPO contracts to drive access and adherence; 2024 channels: wholesalers ~85% distribution, specialty =54% spend, ~6,000 hospitals. Digital (EMR\/eRx +20–30% concordance) and patient apps (+10–25% adherence) complement REMS and PA workflows to reduce abandonment.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eChannel\u003c\/th\u003e\n\u003cth\u003e2024 Metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eWholesalers\u003c\/td\u003e\n\u003ctd\u003e~85% distribution\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSpecialty\u003c\/td\u003e\n\u003ctd\u003e54% drug spend\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospitals\u003c\/td\u003e\n\u003ctd\u003e~6,000 P\u0026amp;T centers\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEMR\/eRx\u003c\/td\u003e\n\u003ctd\u003e+20–30% concordance\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Segments\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePain specialists and anesthesiologists\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePain specialists and anesthesiologists are high-volume prescribers managing complex chronic and perioperative pain—over 50 million US adults report chronic pain and the top 10% of prescribers account for ~55% of opioid prescriptions—so they demand reliable, evidence-backed options with clear risk-mitigation and handling guidance and strongly influence institutional protocols and referral patterns.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePrimary care and urgent care providers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePrimary care and urgent care providers treat acute and sub-acute pain while balancing stewardship; primary care issues roughly half of outpatient analgesic prescriptions and urgent care visits exceeded 100 million annually by 2024. They need clear access pathways, safety education and formulary clarity to meet CMS and state stewardship guidelines. Streamlined prior authorization and concise, time-efficient materials (one-page summaries, 2–3 min videos) speed decisions and reduce treatment delays.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHospitals and integrated delivery networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHospitals and integrated delivery networks (over 6,000 U.S. hospitals) prioritize pathway adherence, patient safety, and cost-effectiveness when evaluating Collegium products, requiring reliable supply and GPO-aligned pricing. FDA REMS has governed ER\/LA opioid risk management since 2012, so REMS compliance and diversion prevention are mandatory contracting terms. Multidisciplinary P\u0026amp;T and opioid stewardship committees drive formulary adoption and usage protocols.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePayers and pharmacy benefit managers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePayers and pharmacy benefit managers prioritize total cost of care and misuse risk mitigation for opioid products, assessing clinical outcomes, budget impact and contracting terms; they demand robust clinical and real-world evidence plus utilization controls such as prior authorization and quantity limits. The three largest PBMs control roughly 80% of U.S. prescription benefits, heavily influencing access and net price.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eManage cost \u0026amp; misuse\u003c\/li\u003e\n\u003cli\u003eEvaluate outcomes, budget impact, contract terms\u003c\/li\u003e\n\u003cli\u003eRequire robust evidence \u0026amp; utilization controls\u003c\/li\u003e\n\u003cli\u003eSensitive to societal and regulatory pressure\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatients and caregivers in pain\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePatients and caregivers seek effective pain relief with manageable side effects, clear dosing instructions and access support; roughly 20% of US adults (≈50 million) report chronic pain, driving demand for financial aid and copay assistance. Adherence coaching and safety resources can improve adherence by up to 20% and must be tailored across ages and health literacy.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eaccess-assistance\u003c\/li\u003e\n\u003cli\u003eadherence-coaching\u003c\/li\u003e\n\u003cli\u003esafety-education\u003c\/li\u003e\n\u003cli\u003etailored-communication\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eREMS, access and PA reform drive care for \u003cstrong\u003e50M\u003c\/strong\u003e US chronic pain\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePain specialists, anesthesiologists, primary\/urgent care, hospitals\/IDNs, PBMs and patients drive Collegium demand: ~50M US adults with chronic pain (≈20%); top 10% prescribers account for ~55% of opioid scripts; urgent care visits \u0026gt;100M (2024); ~6,000 hospitals; top 3 PBMs ~80% market share. Each segment demands REMS-aligned safety, robust evidence, streamlined access\/prior auth, and patient assistance\/adherence support.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSegment\u003c\/th\u003e\n\u003cth\u003e2024 metric\u003c\/th\u003e\n\u003cth\u003ePrimary need\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePain specialists\u003c\/td\u003e\n\u003ctd\u003eHigh Rx share: top10%→55%\u003c\/td\u003e\n\u003ctd\u003eEvidence, risk mitigation\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrimary\/urgent care\u003c\/td\u003e\n\u003ctd\u003e50% outpatient analgesics; 100M visits\u003c\/td\u003e\n\u003ctd\u003eFast tools, PA clarity\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospitals\/IDNs\u003c\/td\u003e\n\u003ctd\u003e≈6,000 US hospitals\u003c\/td\u003e\n\u003ctd\u003eGPO pricing, REMS\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePBMs\/Payers\u003c\/td\u003e\n\u003ctd\u003eTop3≈80% control\u003c\/td\u003e\n\u003ctd\u003eCost\/outcomes, utilization controls\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatients\u003c\/td\u003e\n\u003ctd\u003e≈50M chronic pain\u003c\/td\u003e\n\u003ctd\u003eAccess, copay aid, adherence\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eost Structure\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eR\u0026amp;D and clinical development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePreclinical studies, formulation work and multi-phase trials drive Collegium’s largest R\u0026amp;D outlays, with CRO fees, site costs and data management forming the bulk of trial budgets. Publication, congress funding and medical education add recurring spend to support product uptake. Ongoing life‑cycle and postmarketing studies sustain differentiation around abuse‑deterrent and formulation improvements.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing and COGS\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCollegium’s manufacturing and COGS are driven by CMO fees, API and excipient procurement, and packaging—each compressing margins through unit costs and returns; process validation, QA\/QC and release testing are mandatory steps that add lab and cycle-time expense, while serialization and controlled-substance handling impose regulatory overhead and traceability costs; maintaining redundant suppliers and sites raises resilience but increases fixed and variable COGS.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSales, marketing, and medical affairs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSales, marketing, and medical affairs drive major operating expenses at Collegium, with field force, payer teams, and promotional activities forming the largest line items; in 2024 commercial spend emphasized digital engagement and congress presence requiring dedicated budgets. MSL deployment and educational grants sustain clinical credibility, while CRM and analytics platforms improve targeting and efficiency.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMarket access and rebates\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eRebates, chargebacks and administrative fees paid to wholesalers and PBMs materially reduce Collegium Pharmaceutical’s net price and must be accrued against gross sales.\u003c\/p\u003e\n\u003cp\u003eOutcomes-based agreements can create risk corridors and variable revenue recognition; patient support and copay programs generate ongoing per-patient costs and program administration expenses.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\u003c\/ul\u003e\n\u003cli\u003eRebates\/chargebacks reduce net price\u003c\/li\u003e\n\u003cli\u003eOutcomes agreements create revenue variability\u003c\/li\u003e\n\u003cli\u003eCopay\/support = recurring costs\u003c\/li\u003e\n\u003cli\u003eContract management adds compliance burden\u003c\/li\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory, compliance, and legal\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eREMS administration, pharmacovigilance operations and compliance audits are mandatory for opioid products and in 2024 remained enforced under FDA REMS for extended‑release\/long‑acting opioids. PV and audit programs require continuous monitoring, safety reporting and third‑party inspections. IP prosecution and defense protect the portfolio while licensing and quality agreements demand legal and quality oversight; insurance and governance costs ensure business continuity.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eREMS: FDA 2024 opioid REMS enforced\u003c\/li\u003e\n\u003cli\u003ePV \u0026amp; audits: mandatory ongoing costs\u003c\/li\u003e\n\u003cli\u003eIP \u0026amp; licensing: prosecution, defense, agreements oversight\u003c\/li\u003e\n\u003cli\u003eInsurance \u0026amp; governance: continuity and liability coverage\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eR\u0026amp;D, manufacturing, commercial and compliance costs compress 2024 margins\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eR\u0026amp;D and clinical trials (CRO\/site\/data) are Collegium’s largest variable costs, with ongoing postmarketing studies to support abuse‑deterrent claims. Manufacturing\/COGS reflect CMO fees, API\/packaging and serialization plus redundancy that raise unit costs. Commercial (field, digital, MSLs) and rebates\/PBM chargebacks materially compress gross-to-net; REMS, PV, legal and insurance create fixed compliance overhead in 2024.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eCost line\u003c\/th\u003e\n\u003cth\u003e2024 impact\/notes\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D\/Trials\u003c\/td\u003e\n\u003ctd\u003eHigh; ongoing postmarketing studies\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eManufacturing\/COGS\u003c\/td\u003e\n\u003ctd\u003eCMO, serialization, redundancy raise unit costs\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCommercial\u003c\/td\u003e\n\u003ctd\u003eMajor Opex; digital spend + MSLs\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross-to-net\u003c\/td\u003e\n\u003ctd\u003eRebates\/chargebacks\/PBM reduce net price\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompliance\u003c\/td\u003e\n\u003ctd\u003eREMS, PV, legal and insurance enforced in 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eevenue Streams\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNet product sales (pain and CNS portfolio)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNet product sales totaled $394.4 million in 2024, driven primarily by prescription sales through retail, specialty and hospital channels. Net reflects gross-to-net deductions including rebates, chargebacks and distribution fees that materially reduce gross receipts. Differentiated labeling and REMS-supported positioning can secure premium payer access and higher net pricing. Volume growth remains tied to formulary coverage, prescriber adoption and patient access.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLicensing and technology out-licensing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eUpfront payments and milestone tranches from partners using Collegium’s abuse-deterrent and extended‑release platforms commonly total millions to tens of millions of dollars, providing near‑term cash. Royalties on partnered products, typically in the 5–15% range, create durable, recurring income as partnered SKUs scale. Shared development agreements cut Collegium’s capital needs—often lowering program capex by up to ~50%—while geographic licensing extends commercial reach into additional markets that can add billions to the addressable market. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCo-promotion and co-commercialization\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCo-promotion and co-commercialization generate fees or profit splits (commonly 20–50% in pharma partnerships), letting Collegium share sales income while lowering fixed costs. Access to a partner's broader field force can accelerate uptake, often shortening launch timelines by 3–6 months. This alignment of incentives is especially valuable for new indications or segments, enabling scalable market entry with reduced capex.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEx-US distribution and partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEx-US distribution and partnerships bring territorial agreements that deliver upfront milestones and ongoing royalties, typically in the 8–12% range in comparable 2024 pharma licensing deals, while local partners handle regulatory filings, reimbursement negotiation, and market access to accelerate launches. Technology transfer enables CMO service fees and supply revenues, diversifying demand across multiple markets and reducing single-market exposure.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMilestones + royalties: 8–12% typical\u003c\/li\u003e\n\u003cli\u003eLocal partners: regulatory \u0026amp; market access\u003c\/li\u003e\n\u003cli\u003eTech transfer: CMO and supply income\u003c\/li\u003e\n\u003cli\u003eDiversification: lowers single-market risk\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLifecycle and line-extension revenues\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLifecycle and line-extension revenues for Collegium hinge on new strengths, formulations, or indications that extend Xtampza ER and other assets beyond launch; 2024 sNDA activity and targeted label enhancements drove incremental sales and prescriber uptake. Patient-friendly packaging and device combinations increased pharmacy share and adherence, helping sustain revenue after the initial launch curve. These initiatives convert single-event launches into multi-year cash flows.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024: sNDA-driven uplift\u003c\/li\u003e\n\u003cli\u003eLabel enhancements = incremental sales\u003c\/li\u003e\n\u003cli\u003ePackaging\/devices boost share\u003c\/li\u003e\n\u003cli\u003eSustains post-launch revenue\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e$394.4M sales 2024; royalties, milestones and co-promotion drive recurring cash\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNet product sales were $394.4M in 2024, driven by retail, specialty and hospital channels with gross-to-net deductions. Partner upfronts\/milestones deliver millions–tens of millions while royalties (5–15%) and ex‑US deals (8–12%) create recurring income. Co-promotion splits (20–50%) and tech transfer\/CMO fees diversify cash flow.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024 \/ Range\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet product sales\u003c\/td\u003e\n\u003ctd\u003e$394.4M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRoyalties\u003c\/td\u003e\n\u003ctd\u003e5–15%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePartner milestones\u003c\/td\u003e\n\u003ctd\u003eMillions–tens of millions\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEx‑US royalties\u003c\/td\u003e\n\u003ctd\u003e8–12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"PESTEL Analysis","offers":[{"title":"Default Title","offer_id":58097824301404,"sku":"collegiumpharma-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0938\/8127\/0620\/files\/collegiumpharma-business-model-canvas.png?v=1781791450","url":"https:\/\/pestel-analysis.com\/products\/collegiumpharma-business-model-canvas","provider":"PESTEL ANALYSIS","version":"1.0","type":"link"}